Tag: live attenuated polio vaccine market forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Live Attenuated Polio Vaccine Industry By The Forecast Year 2029?

The live attenuated polio vaccine market has shown significant expansion recently. Projections indicate it will increase from $1.85 billion in 2024 to $1.98 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.3%. The historical drivers for this growth include widespread immunization campaigns, rising concerns about vaccine-derived poliovirus, governmental immunization initiatives, enhanced public awareness and educational efforts, and improved vaccine accessibility and affordability.

The market for the live attenuated polio vaccine is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $2.65 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.6%. Factors driving this growth during the forecast period include enhancements in vaccine stability and shelf life, the re-emergence of polio infections in areas of conflict, a decrease in donor engagement for eradication initiatives, the broadening of routine immunization schedules, and heightened research and development activities focused on creating more secure live attenuated vaccine strains. Key trends anticipated within the same period encompass the appearance of vaccine-derived poliovirus, the ongoing development of oral polio vaccine, innovations in vaccine formulations through technological progress, the incorporation of digital technologies, and collaborative efforts through public-private partnerships.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp

Which Major Market Drivers Are Shaping The Future Of The Live Attenuated Polio Vaccine Market?

Future growth in the live attenuated polio vaccine market is anticipated to be driven by the broadening of immunization programs. These programs represent structured initiatives by governments, health organizations, or other institutions, aimed at delivering vaccines to populations to halt the dissemination of infectious diseases. This expansion largely results from heightened global understanding of disease prevention’s significance and robust backing from governments, international health organizations, and funding bodies. Immunization programs facilitate the live attenuated polio vaccine (LAPV) by guaranteeing extensive distribution, secure administration, and broad coverage, which helps establish herd immunity, prevent virus transmission, and contributes to worldwide polio eradication. As an illustration, information from October 2023, provided by the Centers for Disease Control and Prevention, a US-based national public health agency, indicated that global coverage for the initial dose of the diphtheria-tetanus-pertussis (DTP) vaccine increased from 86% to 89% between 2021 and 2022. Consequently, the increased reach of immunization programs is a key factor propelling the expansion of the live attenuated polio vaccine market.

What Are The Emerging Segments Gaining Attention In The Live Attenuated Polio Vaccine Market?

The live attenuated polio vaccinemarket covered in this report is segmented –

1) By Vaccine Type: Monovalent; Bivalent; Trivalent

2) By Administration Route: Oral Administration; Intramuscular Injection; Subcutaneous Injection

3) By Age Group: Infants (0-1 years); Children (1-5 years); Adults (Above 5 years)

4) By End-User: Hospitals; Clinics; Public Health Agencies; Other End-Users

Subsegments:

1) Monovalent: mOPV1 For Serotype 1

2) Bivalent: Type 1; Type 3

3) Trivalent: Poliovirus Type 1; Poliovirus Type 2; Poliovirus Type 3

Which Competitive Trends Are Defining The Live Attenuated Polio Vaccine Market Structure?

Major companies operating in the live attenuated polio vaccine market are concentrating on securing regulatory approvals to ensure their vaccines meet the safety and efficacy standards required by health authorities globally. Regulatory approvals denote the formal authorization granted by government health agencies or regulatory bodies, permitting a product, such as a vaccine, to be marketed, sold, and used within a specific region or country. For instance, in July 2024, Biological E, an India-based pharmaceutical and biologics company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2), a next-generation live, attenuated oral vaccine designed to tackle the challenges linked with traditional oral polio vaccines. This advanced vaccine is formulated to combat circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks more effectively than its predecessor. nOPV2 is engineered with enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form, which has been a concern with older vaccines.

Who Are The Major Companies Operating In The Live Attenuated Polio Vaccine Market?

Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report

How Do Regional Market Performances Compare Within The Live Attenuated Polio Vaccine Industry?

North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Live Attenuated Polio Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24280&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Polio Vaccine Market 2025, By The Business Research Company

Porcine Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Therapeutic Bcg Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Vaccine Adjuvants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vaccine-adjuvants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Live Attenuated Polio Vaccine Market Size From 2025 to 2034?

The market for live attenuated polio vaccine has witnessed a robust growth in the past few years. The market size, which stood at $1.85 billion in 2024, is expected to swell to $1.98 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.3%. The surge in growth during the historic period is largely due to widespread immunization initiatives, rising cases of vaccine-derived poliovirus, government-sponsored immunization plans, heightened public awareness and education about the disease, and the ease of vaccine access and affordability.

Expectations are high for robust expansion in the live attenuated polio vaccine market in the ensuing years, growing to$2.65 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in this period is ascribed to factors such as enhanced vaccine stability and longevity, the reemergence of polio in volatile regions, wavering dedication from donors to eradication attempts, the enlargement of regular immunization schedules, and a hike in R&D for safer live attenuated vaccine strains. The forecast period is set to see significant trends such as the surfacing of vaccine-derived poliovirus, the production of oral polio vaccines, advancements in vaccine formulation technology, the incorporation of digital technologies, and alliances between public and private sectors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theLive Attenuated Polio Vaccine Market?

The live attenuated polio vaccine (LAPV) market is projected to experience considerable growth due to the expansion of immunization initiatives. Such programs are organized by health bodies, governments, and related institutions with an aim to distribute vaccines and curb the spread of infectious diseases. Increased global cognizance of disease prevention and significant backing from international health organizations, governments, and funding entities predominantly fuel this expansion. Widespread distribution, safe administration, and extensive coverage provided by these immunization programs boost LAPV through the enhancement of herd immunity, prevention of virus propagation, and substantial contributions toward global polio eradication. As an illustration, the Centers for Disease Control and Prevention, a US-based public health agency, reported in October 2023 that the worldwide coverage of the first dose of the diphtheria-tetanus-pertussis (DTP) vaccine has escalated from 86% to 89% between 2021 and 2022. As a result, the accelerating expansion of immunization programs is propelling the LAPV market’s growth.

Which Segments in the Live Attenuated Polio Vaccine Offer the Most Growth?

The live attenuated polio vaccinemarket covered in this report is segmented –

1) By Vaccine Type: Monovalent; Bivalent; Trivalent

2) By Administration Route: Oral Administration; Intramuscular Injection; Subcutaneous Injection

3) By Age Group: Infants (0-1 years); Children (1-5 years); Adults (Above 5 years)

4) By End-User: Hospitals; Clinics; Public Health Agencies; Other End-Users

Subsegments:

1) Monovalent: mOPV1 For Serotype 1

2) Bivalent: Type 1; Type 3

3) Trivalent: Poliovirus Type 1; Poliovirus Type 2; Poliovirus Type 3

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24280&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theLive Attenuated Polio Vaccine Market?# Market?

North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Live Attenuated Polio Vaccine Industry?

Companies leading the live attenuated polio vaccine market are prioritizing the acquisition of regulatory consents, ensuring their vaccines adhere to safety and efficiency standards instituted by global health organizations. Such approvals are formal permissions given by governmental health departments or regulating entities, which authorize the marketing, selling, and usage of a product, like a vaccine, within a particular area or country. For example, in July 2024, Biological E, a pharmaceutical and biologics firm based in India, obtained WHO’s approval for its new oral polio vaccine type 2 (nOPV2). This is an evolved live, oral vaccine aimed at overcoming the issues related to traditional oral polio vaccines. This evolved vaccine is intended to effectively tackle circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks better than the previous ones. Its enhanced genetic stability decreases the probability of the vaccine virus reverting back to a harmful form, an issue usually associated with older vaccines.

View the full report here:

https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report

What Are the Key Elements That Define the Live Attenuated Polio Vaccine Market?

The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) that contains a weakened form of the poliovirus that stimulates a strong immune response without causing disease in healthy individuals. It mimics natural infection, offering long-lasting immunity and helping prevent virus transmission within communities.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24280

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Live Attenuated Polio Vaccine Market Grown from 2024 to 2025?

The market for live attenuated polio vaccines has seen significant growth lately. The market size is projected to increase from $1.85 billion in 2024 to $2.00 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.3%. Factors such as mass vaccination drives, rising concerns over vaccine-derived poliovirus, government-led immunization initiatives, increased public awareness and education, along with the accessibility and affordability of the vaccine, have contributed to the historical period’s growth.

What Growth Rate Is Anticipated for the Live Attenuated Polio Vaccine Market in the Coming Years?

The market for live attenuated polio vaccine is predicted to significantly expand in the forthcoming years. It is projected to reach a value of $2.71 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 7.9%. This growth during the forecasted period can be accredited to factors such as enhanced vaccine stability and longevity, a rise in polio cases in conflict-ridden areas, a lack of enthusiasm from donors in eradication programs, the development of standard immunization initiatives, and an uptick in research for the production of safer live attenuated vaccine strains. Notable trends during this estimated period include the appearance of vaccine-derived poliovirus, progression in the field of oral polio vaccine, advancements in vaccine formulation technology, the incorporation of digital technologies, and collaborations between public and private sectors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp

Who Are the Leading Companies in the Live Attenuated Polio Vaccine Market?

Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited

What Are the Key Drivers of the Live Attenuated Polio Vaccine Market?

The growth of the live attenuated polio vaccine market is anticipated to surge with the broadening of immunization programs. Such programs are concerted initiatives aimed at preventing the spread of infectious diseases through vaccination, undertaken by governments, health bodies, or other organizations. The extension of these programs attributes to a heightened global conscientiousness about disease prevention bolstered by solid backing from governments, international health agencies, and funding entities. Immunization agendas advance the live attenuated polio vaccine (LAPV) market via ensuring an extensive distribution, safe usage, and widespread coverage, thereby contributing to herd immunity, halting virus transfer, and supporting the worldwide eradication of polio. Case in point being in October 2023, as per the US-based Centers for Disease Control and Prevention, global coverage for the initial dose of the diphtheria-tetanus-pertussis (DTP) vaccine escalated from 86% to 89% between 2021 and 2022. As such, the enlargement of immunization programs is fueling the development of the live attenuated polio vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp

What Are the Key Market Segments in the Live Attenuated Polio Vaccine Industry?

The live attenuated polio vaccine market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Bivalent, Trivalent

2) By Administration Route: Oral Administration, Intramuscular Injection, Subcutaneous Injection

3) By Age Group: Infants (0-1 years), Children (1-5 years), Adults (Above 5 years)

4) By End-User: Hospitals, Clinics, Public Health Agencies, Other End-Users

Subsegments:

1) Monovalent: mOPV1 For Serotype 1

2) Bivalent: Type 1, Type 3

3) Trivalent: Poliovirus Type 1, Poliovirus Type 2, Poliovirus Type 3

What Are the Latest Trends in the Live Attenuated Polio Vaccine Market?

Leading corporations in the live attenuated polio vaccine market are prioritizing acquiring regulatory permissions to confirm their vaccines align with the safety and efficiency criteria set by global health agencies. Such approvals are essentially official permissions extended by government health organizations or regulatory entities, facilitating a product like a vaccine’s marketability, sale, and usage within a particular territory or country. For example, in July 2024, Biological E, a pharmaceutical and biologics enterprise based in India, achieved the World Health Organization (WHO)’s approval for its innovative oral polio vaccine type 2 (nOPV2). This modern, live, attenuated oral vaccine is created to tackle the issues related to conventional oral polio vaccines. This advanced vaccine is made to battle outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2) more effectively than the preceding version. nOPV2 is built with high genetic stability, diminishing the possibility of the vaccine virus changing back into a dangerous form, which was a worry with previous vaccines.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report

What Are the Key Regional Markets in the Live Attenuated Polio Vaccine Industry?

North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24280&type=smp

This Report Delivers Insight On:

1. How big is the live attenuated polio vaccine market, and how is it changing globally?

2. Who are the major companies in the live attenuated polio vaccine market, and how are they performing?

3. What are the key opportunities and risks in the live attenuated polio vaccine market right now?

4. Which products or customer segments are growing the most in the live attenuated polio vaccine market?

5. What factors are helping or slowing down the growth of the live attenuated polio vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model